Targeting mutant p53 through the mevalonate pathway.

Abstract excerpt

It is well established that mutant forms of the p53 tumour suppressor acquire pro-oncogenic activities. Inhibition of the mevalonate pathway is now shown to promote degradation of select oncogenic mutant p53 proteins, indicating that destabilization of mutant p53 could be a promising therapeutic strategy.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Apoptosis
• Share to Carcinogenesis
• Share to Mevalonic Acid